

中醫藥學院通訊

SCM NEWSLETTER

2022年12月 | DEC 2022

學院推出「光大關愛·長新冠中醫康復計劃」

SCM launches “Everbright Care • Long COVID
Chinese Medicine Rehabilitation Programme”



專題 **FEATURE**

陳立典教授和陳士林教授榮獲第六屆張安德中醫藥國際貢獻獎

The Sixth Cheung On Tak International Award for Outstanding Contribution to
Chinese Medicine conferred upon Professor Chen Lidian and Professor Chen Shilin

目錄

CONTENTS

專題 Features

學院推出「光大關愛·長新冠中醫康復計劃」 03~06

SCM launches “Everbright Care • Long COVID Chinese Medicine Rehabilitation Programme”

陳立典教授和陳士林教授榮獲第六屆張安德中醫藥國際貢獻獎 07~09

The Sixth Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine conferred upon Professor Chen Lidian and Professor Chen Shilin

研究焦點 Research Focus

學院與理學院共同研發多功能化合物治療阿茲海默症 10~12

SCM and the Faculty of Science jointly develop versatile compound for treating Alzheimer's disease

學院研發用於成骨治療的新型適配子藥物 13~15

SCM develops new aptamer drug for bone anabolic therapies

學術及專業活動

Academic and Professional Activities

學院網上研討會探討中醫藥全球發展 16

SCM webinar draws insights on the global development of Chinese medicine

學院舉辦國際會議探討中醫遠程醫療應對新冠的策略 17

SCM organises international conference to explore TCM telemedicine strategies for combating COVID-19

兩地專家於網上研討會探討中醫藥新發展 18

Local and Mainland experts explore latest Chinese medicine advancements in webinar

學院動態 Highlights 19~28

學生·校友 Students · Alumni 29~30

新面孔 New Faces 31

聯絡資料 Contact Us 32



學院推出 「光大關愛·長新冠中醫康復計劃」

SCM launches “Everbright Care · Long COVID Chinese Medicine Rehabilitation Programme”



(左起) 浸大協理副校長(中醫藥發展)及中醫藥學院臨床部主任卞兆祥教授、浸大校長衛炳江教授、全港社區抗疫連線總召集人陳振彬博士，以及中國光大集團有限公司副總裁劉嘉先生公布推出「光大關愛·長新冠中醫康復計劃」。

(From left) Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of the Clinical Division of SCM; Professor Alexander Wai, President and Vice-Chancellor of HKBU; Dr. Bunny Chan Chung-bun, Chief Convenor of the Hong Kong Community Anti-Coronavirus Link; and Mr. Liu Jia, Vice President of China Everbright Holdings Co. Ltd. announce the launch of the “Everbright Care · Long COVID Chinese Medicine Rehabilitation Programme”.

香港浸會大學中醫藥學院為幫助出現新冠病毒病後遺症(俗稱「長新冠」)的人士，推出「光大關愛·長新冠中醫康復計劃」，由學院中醫師為65歲或以上、曾患新冠病毒病並已經康復的長者，或曾因新冠病毒病而入院並已經康復的人士，提供免費長新冠診症服務和中藥。

該計劃獲全港社區抗疫連線撥款港幣 500萬元支持。有關款項將由光大集團駐港機構贈予連線的抗疫捐款中撥出。

The School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) has launched the “Everbright Care · Long COVID Chinese Medicine Rehabilitation Programme” to help people who suffer from the after-effects of COVID-19 (commonly known as “long COVID”). Under the programme, Chinese medicine practitioners at SCM will provide a free long COVID consultation and medication service to people who were hospitalised due to the virus and have since recovered, and recovered elderly people aged 65 or above.

The programme is supported by a funding of HK\$5 million from the Hong Kong Community Anti-Coronavirus Link. The funding is allocated from the donation made by the Hong Kong office of the Everbright Group to the Link designated for the purpose of fighting COVID-19.

Based on the clinical symptoms and body constitutions of the participants, SCM Chinese medicine practitioners will provide up to four sessions of free Chinese medicine consultations. A maximum of six days of Chinese medicine granules will be prescribed for participants in each consultation session, depending on their actual condition.



卞兆祥教授介紹「光大關愛·長新冠中醫康復計劃」詳情。

Professor Bian Zhaoxiang introduces details of the “Everbright Care • Long COVID Chinese Medicine Rehabilitation Programme”.

學院中醫師會根據參加者的臨床病徵和體質，提供最多四次免費中醫診症服務，每次診症會按實際情況，處方不多於六天的顆粒劑中藥。

浸大校長衛炳江教授表示：「浸大一直站在抗疫前線，推出不同中醫藥防治服務，並提供全面復康支援。現時新冠患者的症狀雖然普遍較輕，但臨床經驗顯示不少患者在病癒後均出現多種後遺症，須長時間跟進治理。我們十分感謝全港社區抗疫連線的鼎力支持，讓我們能夠推出『光大關愛·長新冠中醫康復計劃』，為社區的福祉再出一分力。」

全港社區抗疫連線總召集人陳振彬博士表示：「全港社區抗疫連線發揚『社區抗疫，你我出力』的精神，致力推動社會各界齊心抗疫。浸大一直不遺餘力地幫助社會對抗新冠，是次我們支持浸大推出『光大關愛·長新冠中醫康復計劃』，特別關顧病癒長者，以及曾因感染新冠而入院的市民，冀能為染疫人士提供更加全面到位的復康支援。」

中國光大集團有限公司副總裁劉嘉先生表示：「光大集團1983年發源於香港，長期根植香港、建設香港、服務香港，與香港同心同行。『光大關愛·長新冠中醫康復計劃』將為合資格的人士提供免費診症及醫藥服務。相信本次計劃將進一步發揮中醫藥在抗疫方面的正面作用，支持香港社會平穩度過疫情難關。」

Professor Alexander Wai, President and Vice-Chancellor of HKBU, said: “The University has been at the forefront of fighting the pandemic by using Chinese medicine for prevention and treatment, and providing holistic care for rehabilitation. Although recent observations suggest that the symptoms of COVID-19 are generally mild, clinical experience shows that many patients have multiple issues after recovery and require prolonged follow-up care. We are grateful for the staunch support of the Hong Kong Community Anti-Coronavirus Link for our sustained efforts in promoting the well-being of the community by launching the ‘Everbright Care • Long COVID Chinese Medicine Rehabilitation Programme’.”

Dr. Bunny Chan Chung-bun, Chief Convenor of the Hong Kong Community Anti-Coronavirus Link, said: “The Hong Kong Community Anti-Coronavirus Link promotes the spirit of joining hands to fight against COVID-19 in the community, and it is committed to uniting different sectors of society to combat the disease. As HKBU spares no effort to help society ward off COVID-19, we are supporting the University to launch the ‘Everbright Care • Long COVID Chinese Medicine Rehabilitation Programme’ to offer special care to elderly people and those who have been hospitalised due to the disease, so that more comprehensive and precise support can be provided to people for their COVID-19 rehabilitation.”

協理副校長（中醫藥發展）、學院臨床部主任卞兆祥教授表示：「中醫在治療新冠病毒病的貢獻獲得社會肯定，我們也累積了協助新冠病人康復的寶貴經驗。不少新冠患者在病癒後會出現咳嗽、短氣、失眠、脫髮、皮膚過敏、疲累等『長新冠』症狀，而中醫在治療這些症狀方面具備豐富經驗，成效顯著。我們希望透過計劃，進一步彰顯中醫對抗新冠疫情的效用，舒緩病癒人士的後遺症狀，從而改善他們的生活質素。」

市民須於網上系統 (<https://cmc-booking.hkbu.edu.hk/>) 報名及預約參加計劃。合資格人士須親臨五間指定診所接受第一及第三次診症；第二及第四次診症則會透過手機通訊程式以視像形式進行。四次診症所處方的中藥，均須於指定診所領取。

65歲或以上的新冠病毒病康復長者在首次診症時，須出示以下其中一項證明，包括：

- 獲政府承認的私營醫務化驗所陽性核酸檢測短訊、電子或紙本紀錄；
- 衛生署快速抗原測試陽性結果人士申報系統的成功申報短訊或電子紀錄；
- 衛生署向新冠確診人士發出的隔離令；
- 其他由政府或醫院管理局發出的康復紀錄； 或
- 出院文件。

Mr. Liu Jia, Vice President of China Everbright Holdings Co Ltd, said: "Founded in Hong Kong in 1983, the Everbright Group has long been rooted in the city, and it has heartily contributed to its ongoing development and prosperity. The 'Everbright Care • Long COVID Chinese Medicine Rehabilitation Programme' will offer free consultations and medications to eligible people. We believe this programme will further leverage the positive impacts of Chinese medicine in the fight against the pandemic, and support the Hong Kong community to robustly overcome the challenges of the pandemic."

Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of the Clinical Division of SCM, said: "Chinese medicine's contribution to treating COVID-19 has been recognised by the community, and we have accumulated valuable experience in helping people recuperate from COVID-19 infection. Many recovered patients have 'long COVID' symptoms such as cough, shortness of breath, insomnia, hair loss, skin irritation, and fatigue. Chinese medicine has rich experience in treating these symptoms effectively. Through this programme, we hope to further strengthen the role of Chinese medicine in the fight against the pandemic, and relieve the issues encountered by recovering patients, thus improving their quality of life."

Participants of the programme have to register and make appointments through an online system (<https://cmc-booking.hkbu.edu.hk/>). For the first and third consultation sessions, eligible participants are required to visit the five designated clinics for face-to-face consultations. The second and fourth consultation sessions will be conducted in the form of video conferencing through a mobile phone communication application. The Chinese medicines prescribed at all consultation sessions should be collected at the designated clinics.

Participants who are aged 65 or above and have recovered from COVID-19 should present one of the following documents at the first consultation session:

- SMS, electronic or paper record of a positive nucleic acid test result provided by private medical testing companies recognised by the Government;
- SMS or electronic record of a successful report submission to the Declaration System of Individuals Tested Positive for COVID-19 Using Rapid Antigen Test under the Department of Health;

曾因新冠病毒病入院的康復人士在首次診症時，則須出示出院文件。

除了上述計劃，學院在今年初先後成立「浸大中醫抗疫醫療隊」和「浸大中醫抗疫遠程醫療中心」，向新冠確診者和緊密接觸者提供義診，服務超過41,000人次，共派發逾17萬劑藥物，另有近100間老人院受惠。由疫情爆發至今，學院更分發超過10萬劑浸大防感方，惠澤社群。

此外，浸大獲社會福利署委任為啟德暫託中心的其中一間營運機構，在今年3至5月派出學院中醫師隊伍，為入住中心的新冠輕症長者，提供以中醫為主的治療服務。

- Compulsory quarantine order issued by the Department of Health to the people infected with COVID-19;
- Rehabilitation records issued by the Government or the Hospital Authority; or
- Hospital discharge document.


Recovered patients who were hospitalised due to COVID-19 should present hospital discharge documents at the first consultation session.

Apart from the programme, SCM established the HKBU Chinese Medicine Team Against COVID-19 and the HKBU Chinese Medicine Telemedicine Centre Against COVID-19 earlier this year to provide free consultations to COVID-19 patients and their close contacts, and the service had more than 41,000 patient visits and distributed more than 170,000 doses of medication. In addition, nearly 100 elderly homes were benefited. Since the onset of the pandemic, the School has distributed more than 100,000 doses of HKBU Chinese Medicine Immunity Enhancement Remedy.

HKBU was also appointed by the Social Welfare Department as one of the operators of the Kai Tak Holding Centre. From March to May this year, the University dispatched a team of Chinese medicine practitioners from SCM to provide Chinese medicine-based treatment services to elderly COVID-19 patients with mild symptoms who had been admitted to the Centre.

學院中醫師會為參加者提供診症服務並處方顆粒劑中藥，費用全免。

Under the programme, Chinese medicine practitioners at SCM will offer free consultations and prescribe free Chinese medicine granules for participants.



陳立典教授和陳士林教授榮獲 第六屆張安德中醫藥國際貢獻獎

The Sixth Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine conferred upon Professor Chen Lidian and Professor Chen Shilin

陳立典教授（左）和陳士林教授（右）獲頒第六屆張安德中醫藥國際貢獻獎。

Professor Chen Lidian (left) and Professor Chen Shilin (right) receive the Sixth Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine.



學院於7月13日舉行第六屆張安德中醫藥國際貢獻獎頒獎典禮，頒授獎項予陳立典教授和陳士林教授，以表彰他們在中醫藥領域非凡的學術和科研成就，以及對促進中醫藥現代化和國際化的卓越貢獻。

頒獎典禮在網上舉行，由張安德慈善基金董事張敬智先生、浸大校長衛炳江教授、中國科學院院士兼評審委員會主席陳凱先院士，以及院長呂愛平教授共同主禮。評審委員會委員陳可冀院士、梁秉中教授和蘇國輝教授亦撥冗出席典禮。

SCM presented on 13 July the Sixth Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine to Professor Chen Lidian and Professor Chen Shilin in recognition of their exceptional achievements in scholarship and research in Chinese medicine and their significant contributions to the modernisation and internationalisation of traditional Chinese medicine (TCM).

The award ceremony, which was held online, was officiated by Mr. Gavin Cheung, Director of the Cheung On Tak Charity Foundation; Professor Alexander Wai, President and Vice-Chancellor of HKBU; Professor Chen Kaixian, Academician of the Chinese Academy of Sciences and Chairperson of the Panel of Adjudicators for the Award; and Professor Lyu Aiping, Dean of Chinese Medicine at HKBU. Adjudicators Professor Chen Keji, Professor Leung Ping-chung and Professor So Kwok-fai were also in attendance.

陳立典教授是中西醫結合康復治療專家，獲譽為國家復康領域的先驅及領導人物，一直致力融會中醫理論和現代康復療法。陳教授在多方面取得傑出成就，不僅創建出中醫康復共性技術，還制定了中西醫結合康復臨床規範與標準，獲國內外康復醫療機構廣泛採用。他對中西醫結合康復治療的發展有著無可比擬的貢獻，在行內備受尊崇。

陳士林教授是中國中醫科學院中藥研究所所長暨首席研究員，以及世界衛生組織傳統醫學合作中心主任，專門從事傳統中醫藥質量保證與鑒定研究工作。他成功創立本草基因組學學科，並構建出「全球藥典草藥基因組數據庫」和中草藥 DNA 條碼系統，從基因層面解決長久以來中草藥鑒定的難題，開啟中醫藥鑒定和基因組學的新篇章。

衛炳江教授為活動致開幕辭，他感謝張安德慈善基金鼎力支持大學促進中醫藥發展和國際化的工作，讓學院得以頒發這項殊榮，向一眾為中醫藥國際化及現代化奠定堅實基石和開闢新徑的傑出學者和科學家致敬。衛教授續指，中醫藥在疫情期間漸趨普及，加上本港首家中醫醫院即將於 2025 年投入服務，當下實是全面推動中醫藥現代化和全球化的良機。



(上排左起) 梁秉中教授、陳可冀院士、蘇國輝教授、(中排左起) 陳立典教授、張敬智先生、陳士林教授、(下排左起) 呂愛平教授、衛炳江教授和陳凱先院士出席網上舉行的頒獎典禮。

(From left, top) Professor Leung Ping-chung, Professor Chen Keji, Professor So Kwok-fai, (from left, middle) Professor Chen Lidian, Mr. Gavin Cheung, Professor Chen Shilin, (from left, bottom) Professor Lyu Aiping, Professor Alexander Wai and Professor Chen Kaixian attend the award ceremony held online.

Professor Chen Lidian is a specialist in integrated Chinese and Western medicine in rehabilitation sciences. Hailed as a pioneer and leading figure of rehabilitation medicine in China, Professor Chen has taken upon himself to incorporate TCM theories into modern rehabilitation therapies. Among his manifold accomplishments, Professor Chen has developed generic technologies for TCM rehabilitation and formulated guidelines and standards for the clinical practice of integrated rehabilitation medicine, which have been widely adopted by rehabilitation service providers at home and abroad. Professor Chen is held in high regard in the field for his unparalleled contribution to the development of integrated Chinese and Western rehabilitation medicine.

Professor Chen Shilin is the Director and Chief Researcher of the Institute of Chinese Materia Medica at the China Academy of Chinese Medical Sciences and the Director of the World Health Organization's Collaborating Center for Traditional Medicine. He has devoted his career to the quality assurance and authentication of TCM. Not only did he establish Herbage genomics as a discipline, but he also developed the Global Pharmacopoeia Genome Database and a DNA barcoding system which helped overcome the long-standing challenge of authenticating Chinese herbal medicines at the genetic level. As a result of Professor Chen's research efforts, a new realm of possibilities for authentication of TCM and genomics has been unlocked.


呂愛平教授致辭時，向兩位得獎者送上祝賀並讚揚他們充分運用其他學科的知識，開拓中醫藥的嶄新視野。他指大學現時設有六個跨學科研究實驗室，務求發揮更大的協同效應和研究影響力。他期待學院能與二人合作，從中借鏡他們創新的跨學科研究成果。

陳立典教授在發表得獎感言時表示，這是中西醫結合康復治療首度奪得的榮譽，令他和同儕深受鼓舞。隨著中西醫結合康復基礎和臨床研究不斷取得突破，陳教授深信中西結合康復醫學定能在「健康中國」的建設中發揮更大的作用。陳士林教授則冀望與本港學者和業界專家攜手合作，為中醫藥的蓬勃發展出一分力，更視促進中醫藥標準化和國際化為己任。

兩位得獎者在頒獎典禮後舉行網上講座，吸引近400名業界人士和學院師生參加。陳立典教授的講座主題為「中西醫結合康復的創新與發展」，陳士林教授則以「本草基因組學與中醫藥現代化」為題發表演說。

衛炳江教授祝賀兩位得獎者，並感謝張安德慈善基金對中醫藥發展和國際化的鼎力支持。

Professor Alexander Wai congratulates the two awardees and expresses his gratitude to the Cheung On Tak Charity Foundation for its staunch support for the development and internationalisation of Chinese medicine.



Professor Alexander Wai opened the ceremony with a vote of thanks to the Cheung On Tak Charity Foundation for its support for the University's commitment to the development and internationalisation of Chinese medicine. He said the establishment of the award has enabled SCM to pay homage to distinguished scientists and scholars who have laid the groundwork and paved the way for the internalisation and modernisation of TCM. In view of the growing popularity of Chinese medicine amid the pandemic and the opportunities presented by the city's first Chinese medicine hospital, which is set to commence service in 2025, Professor Wai said it would be high time to heighten efforts on all fronts to push for the modernisation and globalisation of TCM.

Speaking at the ceremony, Professor Lyu Aiping congratulated the two award recipients and applauded their pioneering efforts in bringing in new perspectives from other disciplines to enrich the understanding of TCM. He said the University has established six interdisciplinary research laboratories to achieve greater synergies and research impact and he is eager for the School to collaborate with the two honorees and be inspired by their innovative and transdisciplinary research approach.

On receiving the award, Professor Chen Lidian said it marked the first such recognition for integrated Chinese and Western rehabilitation, which was highly encouraging for him and his peers. As basic and clinical research in integrated rehabilitation medicine continues to achieve breakthroughs, Professor Chen said he believes it is well poised to play an important role in driving the Healthy China Initiative. Professor Chen Shilin expressed his earnest wish to join hands with experts from academia and industry in Hong Kong to contribute to the robust development of TCM. He also vowed to remain steadfast in his efforts to expedite the standardisation and internationalisation of TCM.

Following the ceremony, the two award recipients each delivered an online lecture, attracting close to 400 participants including Chinese medicine professionals as well as staff and students of SCM. Professor Chen Lidian spoke on the topic "Innovation and Development of Integrated Traditional Chinese and Western Medicine in Rehabilitation", while Professor Chen Shilin discussed "Herbgenomics – Bridging Traditional Chinese Medicine and Modern Technologies".

學院與理學院共同研發 多功能化合物治療阿茲海默症

SCM and the Faculty of Science jointly develop versatile compound for treating Alzheimer's disease



李敏教授（中）、黃文成教授（左）和 Iyaswamy Ashok 博士（右）發現化合物 F-SLOH 對治療早期阿茲海默症具有很好的潛力。

Professor Li Min (middle), Professor Ricky Wong Man-shing (left) and Dr. Iyaswamy Ashok (right) found that the compound F-SLOH has promising theragnostic potential for treating Alzheimer's disease at an early stage.

由學院和理學院研究人員領導的研究顯示，一種名為 F-SLOH 的多功能有機化合物，具備治療早期阿茲海默症的潛力。研究團隊發現，該化合物能抑制大腦神經細胞的澱粉樣蛋白 β ($A\beta$) 聚積，並可減輕 tau 蛋白過度磷酸化及神經炎症，從而改善阿茲海默症的病理特徵。這項研究成果已於國際學術期刊《Redox Biology》上發表。

F-SLOH 用作診治阿茲海默症

由教學科研部教授及副院長（教與學）李敏教授、理學院化學系教授黃文成教授，以及教學科研部研究助理教授 Iyaswamy Ashok 博士等組成的研究團隊，致力尋找阿茲海默症的嶄新治療和診斷方法。他們證明一種名為 F-SLOH 的化合物，能降低阿茲海默症小鼠大腦神經細胞的 $A\beta$ 異常聚積、tau 蛋白過度磷酸化水平和神經炎症，從而改善這些小鼠的學習和記憶能力。

A study led by researchers from SCM and the Faculty of Science has demonstrated that a multifunctional organic compound named F-SLOH has the potential to treat Alzheimer's disease (AD) at an early stage. The team found that it can inhibit the aggregation of amyloid-beta ($A\beta$), and reduce the hyperphosphorylation of tau proteins and neuroinflammation in the brain to improve the pathological features of AD. The findings have been published in the international academic journal *Redox Biology*.

AD is the most common cause of dementia. It accounts for nearly 65% of dementia cases in elderly Hong Kong Chinese. It is pathologically characterised by the abnormal aggregation of $A\beta$, the hyperphosphorylation of tau proteins and neuroinflammation in the nerve cells in the brain, which cause progressive neuronal loss and cognitive impairment. Currently there is no cure for AD, and the available medicines can only relieve its symptoms. Inhibiting the abnormal aggregation of $A\beta$ and the hyperphosphorylation of tau proteins is considered the primary and a promising therapeutic approach to treat AD.

F-SLOH as theragnostic agent for AD

In the search for novel therapeutic and diagnostic methods for AD, a research team comprising Professor Li Min, Professor of the Teaching and Research Division (CMTR) and Associate Dean of Chinese Medicine (Teaching and Learning); Professor Ricky Wong Man-shing, Professor of the Department of Chemistry of the Faculty of Science;

F-SLOH 是由黃文成教授團隊合成的多功能花青素探針，用於檢測蛋白質和肽等生物物質。其特點包括能實時顯示大腦中的 A β 聚積、極佳的穿透血腦屏障能力以及低生物毒性。從以往的研究可見，F-SLOH 能抑制多種 A β 異常聚積，同時在體外細胞實驗中，對 A β 異常聚積所產生的神經毒性帶來大腦神經保護作用。

F-SLOH 改善阿茲海默症小鼠的病理特徵

為評估 F-SLOH 治療阿茲海默症的成效，研究人員向一組轉基因阿茲海默症小鼠注射或餵飼 F-SLOH。組織病理學和生物化學分析研究顯示，接受 F-SLOH 治療的小鼠，其海馬體與大腦中的 A β 寡聚體（即其中一種 A β ）和 A β 斑塊沉積物（即 A β 團塊），比沒有接受 F-SLOH 治療的對照組阿茲海默症小鼠顯著減少。

研究人員同時發現，F-SLOH 可降低產生 A β 的澱粉樣前體蛋白水平，以及 tau 蛋白的磷酸化水平。針對轉基因阿茲海默症小鼠進行的大腦免疫印跡分析，也發現 F-SLOH 治療組的澱粉樣前體蛋白及其代謝物水平，顯著低於對照組。

研究人員亦對接受 F-SLOH 治療的轉基因阿茲海默症小鼠進行其他實驗，把可溶性和不可溶性 tau 蛋白從小鼠的腦組織樣本中分離出來。結果顯示，在經 F-SLOH 治療的阿茲海默症小鼠大腦中，不可溶性 tau 蛋白水平顯著降低，而這種蛋白會導致神經纖維纏結，亦即形成阿茲海默症的一大病理特徵。

F-SLOH 改善阿茲海默症小鼠的記憶和認知能力

神經細胞聯繫功能出現障礙，以及記憶力下降，均與 A β 的聚積有著密切關係。研究人員先後展開兩項實驗，以測試阿茲海默症小鼠的記憶力。在第一項實驗中，小鼠須在水迷宮中受訓，游至一個浮台並記住浮台位置。其後，研究人員會移除浮台，從中觀察小鼠能否憶起並游至浮台的原來位置。與對照組相比，以 F-SLOH 治療的轉基因阿茲海默症小鼠在浮台原來位置游弋的時間較長，顯示牠們較能記住浮台的位置。

and Dr. Iyaswamy Ashok, Research Assistant Professor of CMTR, demonstrated the *in vivo* therapeutic efficacy of a compound called F-SLOH in reducing the abnormal aggregation of A β , the hyperphosphorylation of tau proteins and neuroinflammation in the nerve cells in the brain, thereby improving the learning and memory functions of mice with AD.

F-SLOH is a multi-functional cyanine probe synthesised by a team led by Professor Ricky Wong for the detection of biological materials such as proteins and peptides. Its features include real-time visualisation of A β aggregation in brains, excellent permeability across the blood-brain barrier and low bio-toxicity. Previous studies showed that F-SLOH could inhibit the abnormal aggregation of A β species and provide neuroprotection against neurotoxicity induced by the abnormal aggregation of A β *in vitro* at the cellular level.

F-SLOH improves pathological features in AD mice

To determine the therapeutic efficacy of F-SLOH for AD, the researchers injected or fed F-SLOH to a group of transgenic AD mice. Histopathological and biochemical analyses showed that in mice treated with F-SLOH, A β oligomers (one of the A β species) and A β plaque deposits (the clumps of A β) were dramatically reduced in their hippocampus and their brains when compared with the AD mice in the control group who had not been fed F-SLOH.

The researchers also found that F-SLOH can reduce the levels of an amyloid precursor protein that generates A β and tau protein hyperphosphorylation. In an immunoblot analysis of the transgenic AD mice brain, the F-SLOH treatment group showed a significant reduction in the levels of the amyloid precursor protein and its metabolites compared to the control group.

In other experiments on the transgenic AD mice after F-SLOH treatment, the researchers separated the soluble and insoluble tau proteins in their brain tissue samples. The results showed that F-SLOH treatment significantly reduced the levels of insoluble tau protein in the brains of AD mice, which forms neurofibrillary tangles, one of the pathological features of AD.

F-SLOH improves memory and cognitive functions in AD mice

Aggregation of A β is closely related to the dysfunction of the links between nerve cells and memory decline. The researchers conducted two experiments to test the memory functions of AD mice. In the first experiment, mice were trained to swim in a water maze, reach a platform and remember its position. After the platform was removed, researchers observed whether the mice were able to recall and approach the original position of the platform. Compared to the control group, transgenic AD mice treated with F-SLOH spent more time swimming around the platform's original position, showing that they can better memorise the platform's location.

在第二項實驗中，團隊向在封閉盒子裏的小鼠播放聲音訊號，再從盒底向其腳部瞬間發出輕微電擊。翌日小鼠被放回盒內，但不會受到電擊。當研究人員向牠們播放相同的聲音訊號，牠們會因害怕被電擊而繃緊不動。與對照組相比，採用 F-SLOH 治療的轉基因阿茲海默症小鼠繃緊不動的時間較長。

兩項實驗的結果顯示，接受 F-SLOH 治療的阿茲海默症小鼠，其記憶力比對照組優勝，表明 F-SLOH 能改善阿茲海默症小鼠的記憶及認知能力。

F-SLOH 具治療早期阿茲海默症的潛力

研究人員還發現，F-SLOH 透過激活轉錄因子 EB，降解 A β 異常聚積，並降低 tau 蛋白過度磷酸化水平、澱粉樣前體蛋白及其代謝物。轉錄因子 EB 是「自噬 - 溶酶體通路」的主要調節因子，該通路是降解細胞內老化的大分子蛋白（包括 A β 聚集體等細胞內代謝產物）的主要機制。

李敏教授表示：「阿茲海默症患者會隨病情發展而失去自理能力，並須長期接受護理。隨著香港人口老化，相信阿茲海默症的患病率亦會有所提升，故有迫切需要研發新藥物，以治療阿茲海默症或減緩其症狀。是次研究顯示 F-SLOH 化合物對治療早期阿茲海默症具有很好的潛力。」

黃文成教授表示：「這項研究首次提供體內動物實驗的證據，表明 F-SLOH 在阿茲海默症小鼠模型中具一定成效，能針對性治療多種神經退行性病理學的變化。相關研究結果有助推進阿茲海默症的診斷和治療。」

In the second experiment, mice were placed in a chamber and exposed to an audio tone followed by an instant small electric shock to their feet from the floor of the chamber. On the following day, they were put back in the chamber but without any electric shock. When the mice were exposed to the same audio tone, they “froze” their body movements out of the fear of an electric shock. The transgenic AD mice treated with F-SLOH exhibited a longer freezing time than that of the control group.

The results of the two experiments showed that AD mice treated with F-SLOH have better memories compared to the control group, suggesting that F-SLOH improved AD mice’s memory and cognitive functions.

F-SLOH shows early potential for treating AD

The researchers also revealed that F-SLOH degraded the abnormal aggregation of A β and reduced the levels of tau protein hyperphosphorylation, the amyloid precursor protein and its metabolites through the activation of the transcription factor EB. Transcription factor EB is the main regulator of the autophagy-lysosomal pathway, a major mechanism for degrading ageing intracellular macromolecular proteins, including the intracellular metabolites such as A β aggregates.

Professor Li Min said: “AD patients lose their self-management abilities and require long-term care as the disease progresses. As the population is ageing in Hong Kong, the prevalence of AD is likely to increase. There is an urgent need to develop new drugs that can treat or slow down the progression of AD. The current study suggests that the compound F-SLOH has promising therapeutic potential for treating AD at an early stage.”

Professor Ricky Wong said: “The study provides the first *in vivo* evidence that F-SLOH is an effective agent that can target and treat multiple neurodegenerative changes in an AD mouse model. The research findings can drive advancements in AD diagnosis and treatment in humans.”



李敏教授（左）、黃文成教授（右）和 Iyaswamy Ashok 博士（中）的研究首次提供體內動物實驗的證據，表明 F-SLOH 是一種有效的藥物，能針對性治療多種神經退行性病理學的變化。

The study conducted by Professor Li Min (left), Professor Ricky Wong Man-shing (right) and Dr. Iyaswamy Ashok (middle) provides the first *in vivo* evidence that F-SLOH is an effective agent that can target and treat multiple neurodegenerative changes in an AD mouse model.

學院研發用於成骨治療的新型適配子藥物

SCM develops new aptamer drug for bone anabolic therapies

(左起) 于媛媛博士、呂愛平教授、張戈教授，以及羅守輝骨與關節疾病轉化醫學研究所博士後研究學人王璐瑤博士開發新型適配子藥物，以治療骨質疏鬆症和成骨不全症。

(From left) Dr. Yu Yuanyuan, Professor Lyu Aiping, Professor Zhang Ge, and Dr. Wang Luyao, Post-Doctoral Research Fellow of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at SCM, develop the new aptamer drug for osteoporosis and osteogenesis imperfecta.



學院領導的研究團隊發現一個成骨治療的分子標靶，並開發出相應的適配子藥物，作為硬骨抑素抑制劑。硬骨抑素是一種抑制骨骼形成的蛋白。與坊間會增加心血管疾病風險的抗體藥物相比，這項發現為開發有效的骨質疏鬆症和成骨不全症新一代治療方案帶來希望。

相關研究結果已刊登於國際學術期刊《Nature Communications》及《Theranostics》。新藥目前處於臨床研究前開發階段，研究團隊計劃在2024年開始在美國和內地作臨床試驗。

現有藥物增加心血管疾病風險

骨質疏鬆症是一種代謝疾病，會導致骨質密度和強度下降，骨骼因而變得脆弱並更容易折斷。成骨不全症

A research team led by SCM has identified a molecular target for bone anabolic therapies using a selected aptamer that serves as an inhibitor of sclerostin, a protein that prevents bone growth. The discovery offers hope for the development of an effective next-generation treatment for osteoporosis and osteogenesis imperfecta that is free of cardiovascular risk compared to the marketed antibody drug.

The research findings have been published in the international academic journals *Nature Communications* and *Theranostics*. The New drug is at the pre-clinical trial development stage, and the research team plans to start clinical trials in the US and on the Mainland in 2024.

Current medication increases cardiovascular risk

Osteoporosis is a metabolic condition which leads to a reduction in bone density, resulting in weakened bones that are more fragile and likely to break. Osteogenesis

又稱「脆骨症」或「玻璃骨」，是一種罕見的先天性遺傳病，特點是骨骼極之脆弱。硬骨抑素已被識別為骨質疏鬆症和成骨不全症的治療標靶。

美國食品藥物管理局 (FDA) 在 2019 年批准使用抑制硬骨抑素的單抗藥物治療絕經後骨質疏鬆症。研究顯示單抗可提升患有成骨不全症小鼠的骨骼重量和強度。然而，由於硬骨抑素具備保護心血管系統的作用，單抗藥物在臨床試驗中增加了心臟病發、中風和心血管疾病致死的風險，因此被 FDA 要求在藥物上標註心血管風險的黑框警告。

黃英豪博士中醫藥教授兼學院轄下的整合生物信息醫學與轉化科學研究所所長呂愛平教授、羅守輝骨與關節疾病轉化醫學研究所所長張戈教授、以及粵港澳大灣區適配子轉化醫學與藥物發現國際合作平台經理及教學科研部助理教授于媛媛博士領導研究小組，致力開發替代藥物，為病人提供新選擇。

識別「loop3」為新治療標靶

硬骨抑素通過對抗「Wnt 信號通路」抑制骨骼形成。「Wnt 信號通路」調節負責骨骼組織再生的幹細胞，故此抑制硬骨抑素能促進骨骼生長。

研究團隊發現，位於硬骨抑素核心區域的「loop3 結構域」，可成為抑制硬骨抑素的分子標靶。透過基因學研究方法，研究人員發現當硬骨抑素失去 loop3 結構域，它對 Wnt 信號通路的對抗作用會被抑制，但其心血管保護作用則不受影響。這暗示了 loop3 結構域可作為抑制硬骨抑素的分子標靶，同時保留硬骨抑素的心血管保護功能。

研究人員進而篩選可特別抑制硬骨抑素 loop3 的適配子。適配子是單鏈脫氧核糖核酸或核糖核酸分子，可以選擇性地與分子靶標如蛋白質結合。適配子與特定蛋白質結合後，可抑制蛋白質之間的相互作用，從而達到某些治療效果。他們採用組合技術篩選出適配子「aptscl56」，作為以 loop3 結構為標靶的潛在硬骨抑素抑制劑。

imperfecta, also known as “brittle bone disease”, is a rare congenital genetic disorder characterised by extremely fragile bones. Sclerostin has been identified as a therapeutic target for both diseases.

In 2019, the US Food and Drug Administration (FDA) approved the use of the monoclonal antibody against sclerostin for the treatment of postmenopausal osteoporosis. Studies have also shown that sclerostin antibody enhances bone mass and bone strength of mice with osteogenesis imperfecta. However, as sclerostin plays a protective role in the cardiovascular system, it was seen that sclerostin antibody increased the risk of heart attacks, stroke and cardiovascular death during clinical trials. Therefore, a black box warning for potential cardiovascular risks is required by FDA.

A research team led by Professor Lyu Aiping, Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine and Director of the Institute of Integrated Bioinformedicine and Translational Science at SCM; Professor Zhang Ge, Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at SCM; and Dr. Yu Yuanyuan, Manager of the Guangdong-Hong Kong-Macau Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery and Assistant Professor of CMTR, endeavoured to develop alternative drug options.

“Loop3” identified as a new therapeutic target

Sclerostin suppresses bone formation by antagonising the “Wnt signalling pathway”. The “Wnt signalling pathway” modulates the stem cells responsible for skeletal tissue regeneration. Therefore, inhibition of sclerostin promotes bone growth.

The research team discovered that a “loop3 domain” in the core region of sclerostin can be used as a molecular target to inhibit sclerostin. Through genetic studies, it was shown that deficiency of the loop3 domain can inhibit sclerostin’s antagonistic effect against the Wnt signalling pathway, but it does not affect the cardiovascular protective effect of sclerostin. The result suggests that the loop3 domain can serve as a molecular target for inhibiting sclerostin while preserving its cardiovascular protective function.

The researchers then proceeded to screen aptamers that can specifically inhibit sclerostin loop3. Aptamers are single-stranded DNA or RNA molecules that can selectively bind to molecular targets such as proteins. After binding with specific proteins, aptamers may inhibit protein-protein interactions and thereby elicit certain therapeutic effects. Through a combinatorial technology, an aptamer “aptscl56” was selected as a potential sclerostin inhibitor that targets the loop3 structure.

篩選適配子作安全有效硬化素抑製劑

研究團隊分別用骨質疏鬆大鼠模型和成骨不全小鼠模型測試 aptsc156 的治療效能，發現它在兩種模型中都可以有效促進骨骼形成。另一方面，使用 aptsc156 不會增加大鼠和小鼠患上心血管疾病的風險，例如主動脈瘤和動脈粥樣硬化。

在醫學上使用適配子藥物有一定優點，例如對溫度的穩定性和易於合成。然而它們很容易快速降解和被腎臟過濾。研究團隊於是對 aptsc156 的化學特性作出一些調整，製作出一種半衰期更長的適配子「Apc001」。團隊證明 Apc001 可促進骨質疏鬆症大鼠和成骨不全症小鼠的骨骼形成，增加骨骼重量、改善骨骼微結構的完整性，並改善骨骼的活動能力。

臨床試驗計劃在 2024 年展開

張戈教授說：「尋找可靠和安全的替代方案，以解決現有藥物的局限，對幫助需要接受成骨治療的患者至關重要。我們現正進行的研究，從尋找抑制硬骨抑素的分子標靶，到發現適配子藥物，讓我們有望在不久將來開發出新一代硬骨抑素抑製劑。」

呂愛平教授說：「我們為成骨治療尋找其他藥物的選擇，是學術界、業界和政府三方合作的一個好例子。研究工作部分是與本地生物科技公司合作進行，並得到創新及科技基金支持。內地的生物科技公司則參與了某些適配子開發的研究，例如毒理學測試。這些合作將繼續帶來更大的協同效應和豐碩成果。」

適配子 Apc001 已於 2019 年獲得美國食品藥物管理局的孤兒藥認定，以治療成骨不全症。

Aptamer selected as effective and safe sclerostin inhibitor

The research team examined aptsc156's therapeutic functions with osteoporotic rat models and osteogenesis imperfecta mouse models. They found that aptsc156 effectively promotes bone formation. On the other hand, the application of aptsc156 does not increase the risk of developing cardiovascular diseases such as aortic aneurysms and atherosclerotic development in both models.

The medical use of aptamers confers certain advantages, such as thermal stability and ease of synthesis. However, they are prone to rapid degradation and renal filtration. The research team therefore modified aptsc156 to produce an aptamer named "Apc001" with a longer half-life. The team demonstrated that Apc001 promotes bone formation, increases bone mass, improves bone microarchitecture integrity, and enhances bone mechanical properties in rats with osteoporosis and mice with osteogenesis imperfecta.

Clinical trials due to start in 2024

"Searching for reliable and safe alternatives to overcome the limitations of the currently available drugs is crucial to help patients who need bone anabolic therapies. Our ongoing studies, which span from identifying molecular targets for sclerostin inhibition to aptamer drug discovery, offer hope for the development of next-generation sclerostin inhibitors in the near future," said Professor Zhang Ge.

"Our search for alternative drugs for bone anabolic therapies is a good example of tripartite collaboration between academia, industry and the government. The research work was partly conducted in collaboration with a local biotechnology company, and it was supported by the Innovation and Technology Fund. Some biotechnology companies in the Mainland were engaged in certain aspects of developmental research for the aptamer, such as toxicology tests. The collaborative efforts will continue to create more synergy and fruitful results," said Professor Lyu Aiping.

The therapeutic aptamer Apc001 was granted orphan drug designation by the FDA for the treatment of osteogenesis imperfecta in 2019.

學院網上研討會探討中醫藥全球發展

SCM webinar draws insights on the global development of Chinese medicine



學院與香港中西醫結合醫學會（醫學會）在 8 月 21 日合辦題為「二十一世紀中醫藥全球發展策略」的網上研討會。

開幕典禮由香港特別行政區政府醫務衛生局局長盧寵茂教授、行政會議成員及醫學會名譽會長高永文醫生、醫院管理局及香港大學校務委員會前主席梁智鴻醫生、校長衛炳江教授及院長呂愛平教授共同主持。

盧教授在開幕典禮上致辭時表示，由浸大營運的全港首間中醫醫院，以及由衛生署管理的政府中藥檢測中心均於 2022 年動工興建，實是香港中醫藥發展的重要里程碑。他深信這兩大建設將有助推動香港中醫藥的發展更上一層樓。

衛教授致歡迎辭時表示，隨著政府在各方面將中醫藥逐步融入公共醫療體系，中醫藥在香港的地位正不斷提升。他相信，國家中醫藥管理局公布的《粵港澳大灣區中醫藥高地建設方案（2020-2025 年）》能夠為中醫藥界開拓更多新機遇，進一步發揮中醫藥的潛力。

是次活動廣邀來自世界各地的藥物科學、中西醫結合和生物醫學專家，以及大學管理層擔任主講嘉賓，他們在四個專題研討環節上與超過 400 名參加者分享真知灼見，主題涵蓋「國際法規及政策」、「香港高等教育院校的科研發展」、「國家『十四五』規劃的關鍵績效指標」和「產業及市場——大灣區透視」。

SCM co-hosted a webinar entitled “21st Century Chinese Medicine Internationalisation Strategy” with the Hong Kong Association for Integration of Chinese-Western Medicine (HKAIM) on 21 August.

Officiating at the opening ceremony were Professor Lo Chung-mau, Secretary for Health of the HKSAR Government; Dr. Ko Wing-man, Member of the Executive Council of the HKSAR Government and Honorary President of HKAIM; Dr. Leong Che-hung, Former Chairman of the Hospital Authority and the Council of The University of Hong Kong; Professor Alexander Wai, President and Vice-Chancellor of HKBU; and Professor Lyu Aiping, Dean of Chinese Medicine at HKBU.

Addressing the participants at the opening ceremony, Professor Lo said 2022 marks a significant milestone for the development of Chinese medicine in Hong Kong, as the construction of two pieces of flagship infrastructure started in the year. They include the city's first Chinese Medicine Hospital operated by HKBU, and the Government Chinese Medicines Testing Institute managed by the Department of Health. He said these two facilities will without a doubt take the development of Chinese medicine in Hong Kong to the next level.

In his welcome remarks, Professor Wai said Chinese medicine is being increasingly recognised in Hong Kong in light of the Government's ongoing efforts to integrate Chinese medicine into the public health system. He believes that the issuance of the Construction Plan for the Chinese Medicine Highlands in the Guangdong–Hong Kong–Macao Greater Bay Area (2020–2025) by the National Administration of Traditional Chinese Medicine will open up even more new opportunities for Chinese medicine and further unleash its potential.

The event featured distinguished speakers from around the world, including experts in pharmaceutical sciences, integrative medicine and biomedicine as well as university leaders. They shared their valuable insights with over 400 participants at four different panel sessions which addressed the themes of “International Regulations and Policies”, “Research and Development in Hong Kong Universities”, “National 14th Five-Year Plan – Key Performance Indicators” and “Industry and Markets – Perspectives from the Greater Bay Area”.

學院舉辦國際會議探討中醫遠程醫療應對新冠的策略

SCM organises international conference to explore TCM telemedicine strategies for combating COVID-19



Telemedicine has been around for decades but it was not until the COVID-19 pandemic that it began to gain popularity among Chinese medicine practitioners and their patients. As one of the first local health care providers to roll out online consultation services during the pandemic, SCM joined hands with the World Federation of Acupuncture-Moxibustion Societies (WFAS) to host The 1st International Conference on Traditional Chinese Medicine Tele-healthcare (ICTCMT) on 26-27 August.

遠程醫療已發展數十載，但直至近年新冠疫情肆虐，才漸受中醫師及病人的關注。疫情期間，學院成為本港首批推出網上諮詢服務的醫療機構之一，更於 8 月 26 至 27 日聯同世界針灸學會聯合會（世針聯）舉辦第一屆中醫遠程醫療國際研討會。

是次網上活動匯聚來自 10 個國家合共 50 名學者、業界精英和中醫師，深入討論各大議題，包括新冠症狀和新冠後遺症的治療、大數據和循證實踐的應用、中草藥產品的質量控制和供應鏈、遠程醫療保健的資訊科技應用、遠程醫療的監管架構，以及香港和海外遠程醫療實踐的倫理問題。

呂愛平院長在開幕典禮上向逾 5,000 名參加者致歡迎辭。他表示，新冠疫情對醫療保健行業帶來前所未有的挑戰，但同時加快了中醫藥數碼化的步伐，並引發中醫遠程醫療的新一輪研究。

世針聯主席劉保延教授在致辭時指出：「踏入 5G 時代，無線通訊技術發展一日千里，為中醫藥開拓不少新機遇。在疫情下，遠程醫療盡展優勢，這亦促使中醫藥能夠以更高效和更便捷的方式接觸更多受眾。」

研討會籌組委員會主席暨學院副教授張世平博士亦藉此機會向與會者介紹其團隊研發的智能手機舌像拍攝方法，旨在帶來更準確的遙距診斷。他同時鼓勵與會者善用研討會專頁上 (<http://tastcmi.org/1stICTCMT/>) 的論文集，作為中醫遠程醫療實踐的參考資料。/

The online event brought together a total of 50 scholars, industry leaders and practitioners from 10 countries to speak on topics such as the treatment of COVID-19 symptoms and post-COVID syndromes, the use of big data and evidence-based practice, quality control and supply chain of herbal products, application of information technology in tele-healthcare, regulatory framework for telemedicine, as well as ethical concerns relating to the practice of telemedicine in Hong Kong and overseas.

Addressing an audience of over 5,000 people at the opening ceremony, Dean Lyu Aiping said the COVID-19 pandemic posed unprecedented challenges to the healthcare industry, but it also accelerated the digitalisation of Chinese medicine and spurred a new wave of studies into TCM telehealth.

Professor Liu Baoyan, President of WFAS, said in his opening remarks: "The rapid advancement of wireless communication technology in the 5G era has opened up new possibilities for Chinese medicine. With telemedicine coming into its own during the COVID-19 pandemic, Chinese medicine has been able to reach more people in a more cost-effective and efficient manner."

Dr. Zhang Shi-ping, Chair of the Organising Committee of ICTCMT and Associate Professor of SCM, took the opportunity of the occasion to introduce the smartphone tongue imaging method developed by his team to enable more accurate telediagnosis. He encouraged participants to make use of the conference proceedings on the event website (<http://tastcmi.org/1stICTCMT/>) as a useful guide for the practice of TCM telemedicine. /

兩地專家於網上研討會探討中醫藥新發展

Local and Mainland experts explore latest Chinese medicine advancements in webinar



The School joined hands with the Hong Kong Association of Herbal Pharmacology, the Hong Kong Pharmacology and Toxicology Club, the Shanghai Pharmaceutical Association and the Shanghai Pharmacological Society to hold an online conference on 13 August, sharing insights on the latest advancements in Chinese medicine research and development. More than 500 researchers and students tuned in to the live webinar.

Officiating at the opening ceremony were Professor

學院聯同香港中藥藥理學會、香港藥理學家與毒理學家俱樂部、上海市藥學會和上海市藥理學會，在 8 月 13 日舉辦網上研討會，就中醫藥最新研究和發展交流意見，吸引逾 500 名科研人員和學生參加。

浸大副校長（研究及拓展）郭毅可教授、香港中文大學中醫學院院長林志秀教授、上海中醫藥大學中藥學院名譽院長徐宏喜教授，以及院長呂愛平教授一同主持研討會的開幕典禮。

研討會以「面向臨床未被滿足的需求」為主題，邀得內地及本港多所高等院校的頂尖藥物和生物醫學專家擔任講者。與會者暢談他們在轉化醫學與藥物發現方面的跨學科協作成果，特別是有關內分泌、心臟代謝紊亂疾病與癌症的治療對策。與會者亦深入探討結構藥理學、適配子、表型組學、人工智能等創新藥物研發領域的前沿技術。

是次網上研討會乃各個主辦機構首度合辦的年度學術盛會，旨在回顧並匯報機構之間在藥物研發領域的聯合研究進展和成果。學院亦積極制定策略，拓展其學術合作夥伴網絡，全力提升學院藥物研發方面的實力。學院的創新藥物研究基地座落於香港科學園，由粵港澳大灣區適配子轉化醫學與藥物發現國際合作平台、中藥創新研發中心和香港中醫藥表型組學研究中心組成。/

Guo Yike, Vice-President (Research and Development) of HKBU; Professor Lin Zhixiu, Director of the School of Chinese Medicine at The Chinese University of Hong Kong; Professor Xu Hongxi, Honorary Dean of the School of Pharmacy at Shanghai University of Traditional Chinese Medicine; and Professor Lyu Aiping, Dean of Chinese Medicine at HKBU.

Entitled “Addressing the unmet clinical needs”, the webinar gathered a group of leading scholars of pharmaceutical and biomedical sciences from local and Mainland universities as speakers. During the event, they shared the findings from their collaborative and interdisciplinary research in translational medicine and drug discovery with a focus on the treatment of endocrine and cardiometabolic disorders and cancer. Cutting-edge approaches to innovative drug discovery and development, such as structural pharmacology, aptamers, phenomics and artificial intelligence, were also discussed.

The online conference marked the first annual academic meeting for the organising institutions to review and report on the progress and outcomes of their joint research endeavours in drug discovery and development. SCM has been strategically expanding its network of academic partnerships to maximise the research capacity of its innovative drug research hub at the Hong Kong Science Park, which comprises the Guangdong – Hong Kong – Macao Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery, Centre for Chinese Herbal Medicine Drug Development and the Hong Kong Traditional Chinese Medicine Phenome Research Centre./

學院九位教職員榮獲傑出表現獎

Nine staff members of SCM receive awards for outstanding performance



大學於 5 月 24 日舉行教學人員傑出表現頒獎典禮，以嘉許教職員的卓越成就和貢獻。學院共有九位成員獲獎，包括：

傑出新晉教員教學表現獎

教學科研部二級講師蔡嘉傑博士

傑出新晉研究學者獎

教學科研部助理教授王凱亮博士

傑出研究指導獎

教學科研部教授陳虎彪教授

學院優秀教學表現獎

教學科研部高級講師郭平博士

學院優秀學術研究表現獎

教學科研部教授楊智鈞教授

學院優秀服務表現獎

臨床部中醫臨床教授劉鑫教授

創新科技獎

教學科研部助理教授于媛媛博士

知識轉移獎

由臨床部主任卞兆祥教授、中醫臨床助理教授張振海醫師，以及浸大其他學系的專家和支援人員組成的跨學科團隊

院長呂愛平教授恭賀一眾得獎者，並感謝他們默默耕耘，與學院攜手推動教育、研究和服務工作，精益求精。 /

The University held the Awards Presentation for Outstanding Performance Ceremony on 24 May to recognise the distinguished achievements and contributions of staff members. Among those honoured at the event were nine faculty members of SCM. They include:

President's Award for Outstanding Performance in Early Career Teaching

Dr. Chua Ka-kit, Lecturer II of CMTR

President's Award for Outstanding Performance as Early Career Researcher

Dr. Wong Hoi-leong, Assistant Professor of CMTR

President's Award for Outstanding Performance in Research Supervision

Professor Chen Hubiao, Professor of CMTR

School Performance Award in Individual Teaching

Dr. Guo Ping, Senior Lecturer of CMTR

School Performance Award in Scholarly Work

Professor Yang Zhijun, Professor of CMTR

School Performance Award in Service

Professor Liu Xin, Professor of Practice of CLNC

Innovation Award

Dr. Yu Yunayuan, Assistant Professor of CMTR

Knowledge Transfer Award

A transdisciplinary team comprising Professor Bian Zhaoxiang, Director of CLNC; Mr. Cheung Chun-hoi, Assistant Professor of Practice of CLNC; as well as experts and supporting personnel from other HKBU departments and offices.

In his congratulatory message, Professor Lyu Aiping, Dean of SCM, expressed his gratitude to the award recipients for their unwavering dedication to the School's mission of excellence in education, research and service. /

浸大頒授榮譽理學博士學位予 Timothy John Mitchison 教授

HKBU confers the degree of Doctor of Science, *honoris causa*,
upon Professor Timothy John Mitchison



大學於 11 月 21 日舉行頒授典禮，向 Timothy John Mitchison 教授及另外三位傑出人士授予榮譽博士學位。Mitchison 教授是享譽盛名的細胞生物學家和系統生物學家，亦是深得學院信賴的研究夥伴。在典禮開始前，學院有幸邀得 Mitchison 教授以「微管藥物如何發揮醫療作用？」為題，向近 150 名研究人員和學生發表演講。Mitchison 教授現為哈佛大學哈西卜·薩巴格系統生物學講座教授，更是哈佛大學化學和細胞生物學研究所所長及聯合創辦人。他和研究所的同事率先利用基於表型的藥物篩選技術，用「高通量」方法有效「敲除」沒用的遺傳成分，從而加快將這一技術落實應用為治療方法。他亦獲公認為細胞擾動工具的創造者，相關工具用於記錄亞細胞環境中的模式化反應，以及研發治療方法。/


Professor Timothy John Mitchison, an acclaimed cell biologist and systems biologist and a trusted research partner of SCM, was among the four distinguished persons to be awarded an honorary doctoral degree by the University at the Conferment Ceremony held on 21 November. Before the ceremony, the School had the pleasure of hosting a distinguished lecture titled “How do microtubule drugs act as medicines?” by Professor Mitchison, which attracted close to 150 researchers and students. Professor Mitchison is currently the Hasib Sabbagh Professor of Systems Biology at Harvard University. He is also the director and co-founder of the Institute for Chemistry and Cell Biology at Harvard, in which he and his colleagues first piloted phenotype-based drug-screening techniques, whose “high-throughput” volume established the necessary “knockouts” of unwanted genetic constituents, hence accelerating prototyping for therapeutic development. He is duly credited as the creator of the tools of perturbation used to document patterned responses in subcellular environments as well as for their refinement for therapeutic applications./

卞兆祥教授獲香港特區政府頒授榮譽勳章

Professor Bian Zhaoxiang awarded Medal of Honour by HKSAR Government

曾肇添中醫藥臨床研究教授兼臨床部主任卞兆祥教授於 11 月 6 日在香港禮賓府舉行的二〇二二年度勳銜頒授典禮上，獲行政長官李家超先生授予榮譽勳章，以表彰他對本港中醫藥發展和規管事務的貢獻。過去 20 年來，卞教授一直站在前線倡導把中醫藥納入本港醫療體系，以及設立全港首間中醫醫院。他亦率領團隊制定更準確可靠的中藥複方臨床試驗報告指引，在行內備受尊崇。/

In commendation of his contributions to the development and regulatory affairs of Chinese medicine in Hong Kong, Professor Bian Zhaoxiang, Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies and Director of CLNC, was conferred the Medal of Honor by the Chief Executive Mr. John Lee at the 2022 Honours and Awards Presentation Ceremony at Government House on 6 November. Professor Bian has been on the front lines of advocating for the incorporation of Chinese medicine into the healthcare system in Hong Kong and the establishment of the city's first Chinese medicine hospital over the past two decades. He is also widely acclaimed in the field for taking the lead in developing guidelines for more accurate and reliable reporting of clinical trials with Chinese herbal medicines formulas./



趙中振教授獲浸大頒授榮休教授名銜

Professor Zhao Zhongzhen bestowed emeritus status by HKBU



教學科研部講座教授趙中振教授於 8 月正式榮休，他於 6 月 30 日舉行的員工嘉許頒獎典禮上，獲大學頒授榮休教授名銜。趙教授用心服務學院長達 23 載，在推動中醫藥傳承方面，一直不遺餘力，而且屢創先河。他不僅帶領學院規劃全港首個及迄今唯一一個由教資會資助的全日制中藥本科課程，更籌組創立孔憲紹博士伉儷中醫藥博物館和中國銀行（香港）中藥標本中心，並開展《本草綱目》文化工程。趙教授具備超卓領導才能和豐富中醫藥知識，對學院發展影響甚鉅。他將繼續以學院榮休教授和博物館名譽顧問的身份，為學院出謀獻策。 /

Professor Zhao Zhongzhen who retired from SCM as Chair Professor of CMTR in August was conferred the title of Professor Emeritus by the University at the Milestone In Service Ceremony on 30 June. In his 23 years of dedicated service to SCM, Professor Zhao has put himself at the forefront of countless efforts to promote the inheritance of Chinese medicine. From leading the development of the first and only UGC-funded

full-time undergraduate programme in pharmacy in Chinese medicine in Hong Kong to building the Dr. & Mrs. Hung Hin Shiu Museum of Chinese Medicine and The Bank of China (Hong Kong) Chinese Medicines Centre and launching the Compendium of Materia Medica Cultural Project, Professor Zhao's insightful leadership and vast knowledge of Chinese medicine were instrumental in the growth of SCM. He will continue to lend his expertise to the School in his roles as Professor Emeritus of SCM and Honorary Consultant of the museum. /

學院學者榮登全球前 2% 頂尖科學家排行榜

SCM scholars rank among world's top 2% most-cited scientists

學院九位學者近日躋身全球前 2% 頂尖科學家排行榜，包括卞兆祥教授、陳虎彪教授、韓全斌教授、賈偉教授、呂愛平教授、陳可瑜博士、易濤博士、張戈教授和張宏杰教授（按英文姓氏排序）。美國史丹福大學的研究團隊每年會依據學術文獻引用次數等指標評估各領域學者的研究成果，並發布相關排名。 /

Nine scholars from SCM have recently been listed among the world's top 2% of the most-cited scientists. They are Professor Bian Zhaoxiang, Professor Chen Hubiao, Professor Han Quanbin, Professor Jia Wei, Professor Lyu Aiping, Dr. Tan Hor-yue, Dr. Yi Tao, Professor Zhang Ge and Professor Zhang Hongjie (in alphabetical order by surname). The ranking is based on the "Updated science-wide author databases of standardized citation indicators", compiled and announced annually by a group of researchers at Stanford University, US. /

學院聯同內地學者研究草藥基因組

SCM joins forces with Mainland scholars to research into herb genomes

呂愛平院長於 7 月 2 日出席在成都中醫藥大學舉行的「千種本草基因組計劃」發布會。為全面落實該計劃，由成都中醫藥大學陳士林教授牽頭、呂愛平教授等學者共同發起的研究聯盟亦在會上正式成立。「千種本草基因組計劃」研究聯盟匯聚全國 60 多個科研團隊，合力研究中國、印度、歐盟、美國、日本、韓國、巴西等地藥典收編的過千種藥用植物物種，為藥用植物的新品種選育、合成生物學，以及瀕危藥用植物就地及遷地保護工作提供科學基礎。 /

Dean Lyu Aiping attended the launch ceremony of the 1K Herb Genomes Project held at Chengdu University of Traditional Chinese Medicine (CDUTCM) on 2 July. The event also saw the establishment of a research consortium, led by Professor Chen Shilin of CDUTCM, and initiated by Professor Lyu and other scholars, to take forward the project. Drawing on the combined strengths of more than 60 research teams from across the country, the 1K Herb Genomes Project will research into over 1,000 medicinal plants covered in the pharmacopoeias of China, India, the EU, the US, Japan, Korea, Brazil and others. It aims to provide scientific support for the selection and cultivation of new varieties, synthetic biology, as well as *in situ* and *ex situ* conservation of endangered species of medicinal plants. /

浸大與華創簽署備忘錄 探討共建智慧中醫中心

HKBU and CRE sign MOU to explore the establishment of a joint centre on smart Chinese medicine

大學與華潤創業有限公司（華創）在 5 月 26 日簽署合作備忘錄，共同推進中醫藥現代化和國際化。雙方亦按備忘錄的合作框架簽訂意向書，探討成立「浸大—華潤智慧中醫聯合創新中心」，藉以發展並落實智慧中醫、中藥現代化研發和中醫中藥知識產權的合作項目。在五年的合作期內，華創將投入高達港幣 5,000 萬元的資金，並提供市場需求及行業知識、產業資源和管理經驗，以推動相關合作專項。雙方日後會繼續就個別中醫中藥專項合作進行討論並達成協議，再由學院及華創旗下的華潤科學技術研究院負責執行。 /

The University signed a Memorandum of Understanding (MOU) with China Resources Enterprise Limited (CRE) on 26 May to jointly promote the modernisation and internationalisation of Chinese medicine. Under the MOU's collaboration framework, the two parties signed a Letter of Intent to explore the establishment of the HKBU-CRE Joint Innovation Centre on Smart Chinese Medicine to develop and follow through with collaboration initiatives on smart Chinese medicine, research and development of modern Chinese medicines and the intellectual property of Chinese medicine and pharmacy. During the five-year collaboration period, CRE will invest funding of up to HK\$50 million and offer market demand and industry knowledge, industry resources as well as management experience to drive relevant collaboration projects. Both parties will continue to discuss and conclude agreements on designated Chinese medicine and pharmaceutical projects in the future for implementation by SCM and the China Resources Research Institute of Science and Technology under CRE. /



學院與大灣區醫院及院校簽訂兩項合作協議

SCM signs two collaboration agreements with medical and academic institutions in Greater Bay Area

學院於 8 月 25 至 26 日在中山舉行的第四屆粵港澳大灣區中醫藥傳承創新發展大會上簽訂兩項協議，進一步鞏固學院在大灣區的策略夥伴關係。根據學院與中山陳星海中西醫結合醫院在會上簽訂的合作框架協議，雙方將集結資源，發揮各方優勢，共建技術轉化平台和創新服務平台，並為醫護人員提供培訓。另一項協議由學院與廣州中醫藥大學第一附屬醫院和澳門科技大學簽訂，三方將組成聯盟，以提升區內中醫經典教學的整體水平為目標。副院長（教與學）李敏教授於 8 月 28 日代表學院出席聯盟主辦的首場教學研討會，與超過 416,500 名網上觀眾分享學院中醫經典課程的設計和教學方式。 /

At the 4th Guangdong-Hong Kong-Macao Greater Bay Area Conference on Inheritance, Innovation and Development of Traditional Chinese Medicine held in Zhongshan on 25-26 August, SCM signed two agreements to foster its strategic partnerships in the Greater Bay Area. The one signed with Zhongshan Chenxinghai Hospital of Integrated Traditional Chinese and Western Medicine outlines the framework for the two parties to pool their resources and strengths to create a technology transfer platform, innovative service platform as well as training programmes for medical staff. Under the other agreement, which was signed with the First Affiliated Hospital of Guangzhou University of Chinese Medicine and the Macau University of Science and Technology, an alliance will be formed with the goal of elevating the overall standard of the teaching of Chinese medicine classics in the region. On behalf of the School, Professor Li Min, Associate Dean of Chinese Medicine (Teaching and Learning), attended the first teaching and learning seminar hosted by the alliance on 28 August, in which she shared with over 416,500 online viewers the design and pedagogy of SCM's courses on Chinese medicine classics. /

潘機澤伉儷捐款港幣 100 萬元資助學院研究

Mr. Poon Kei-chak and Mrs. Miraner Poon contributes HK\$1 million towards research at SCM



浸大獲潘機澤伉儷捐贈港幣 133 萬元，當中 100 萬元用以支持中醫藥研究。為鳴謝二人慷慨捐款，大學於 5 月 16 日舉行支票致送儀式。潘機澤先生在活動上表示，他欣悉政府委任浸大營運香港首間中醫醫院，充分肯定大學在香港中醫藥發展的領導地位。潘氏伉儷自 2001 年屢次資助浸大各個發展計劃和項目，當中包括中醫藥學院發展基金，對大學一直貢獻良多。 /

Mr. Poon Kei-chak and Mrs. Miraner Poon made a generous donation of HK\$1.33 million to HKBU, of which \$1 million will be

used to support Chinese medicine research. At the cheque presentation ceremony held in appreciation of the donors' beneficence on 16 May, Mr. Poon said he is delighted that the Government has entrusted HKBU with the operation of Hong Kong's first Chinese medicine hospital, which is a recognition of the University's leading role in the development of Chinese medicine in Hong Kong. Mr. and Mrs. Poon are long-standing supporters of HKBU. Since 2001, they have made multiple donations to HKBU for various development projects and initiatives, including the School of Chinese Medicine Development Fund. /

浸大獲陳書賢基金捐贈港幣 100 萬元支持中醫藥長新冠研究

Chan Shu Yin Foundation donates HK\$1 million to HKBU to fund Chinese medicine research on long COVID

大學獲陳書賢基金有限公司慷慨捐贈港幣 100 萬元，以成立陳書賢中醫藥臨床研究基金，支持新冠病毒病後遺症的中醫藥研究。浸大校長衛炳江教授在 9 月 20 日舉行的支票致送儀式上，衷心感謝基金主席陳書賢先生對浸大的鼎力支持。他指是次捐款將襄助大學加強研究，發揮中醫藥的優勢，從而制定最佳的長新冠治療或紓緩方案。 /



The University received a generous donation of HK\$1 million from Chan Shu Yin Foundation Ltd. to establish the Chan Shu Yin Chinese Medicine Clinical Research Fund. The Fund will support Chinese medicine research on post-COVID-19 conditions. At the cheque presentation ceremony on 20 September, Professor Alexander Wai, President and Vice-Chancellor of HKBU, expressed his gratitude to Mr. Burton Chan Shu-yin, Chairman of Chan Shu Yin Foundation Ltd., for his staunch support of HKBU. He said the donation will enable the University to strengthen its research and leverage the strengths of traditional Chinese medicine so as to develop better treatments or relief plans for long COVID. /

學院推動跨院校虛擬實體學習

SCM leads cross-institutional virtual reality learning project

學院骨傷科教學團隊獲教資會的教學發展及語文培訓補助金撥款港幣 100 萬元，與中大的中醫藥學院攜手展開為期兩年的虛擬實體教學項目。團隊會為學生安排服務學習活動，讓他們有機會把課堂所得的骨傷科知識和技巧付諸實踐，學以致用。活動後學生會總結經驗並從中汲取靈感，為虛擬實體學習平台製作互動教材。他們的創作成果不僅會在同儕之間分享，更會通過平台傳承給日後的學生，藉此體現互助學習的精神，並發揮學生主導教學的優勢。 /

With HK\$1 million in funding from the Teaching Development and Language Enhancement Grant of the UGC, the teaching team of Orthopaedics and Traumatology at SCM joined hands with its counterparts at CUHK and HKU to roll out a two-year project that applies virtual reality in teaching and learning. Under this project, students will participate in service-learning activities where they will put their orthopaedic knowledge and skills acquired in class into practice. They will then draw inspiration from their experience to produce educational content with interactive elements for a virtual reality learning platform. The fruit of their creativity will not only be shared among themselves but also be passed down to the next cohort of students through the platform to promote peer-to-peer and student-led learning. /

學院與理大獲教資會撥款港幣 100 萬元共同開展虛擬教學項目

Virtual teaching project developed with PolyU granted HK\$1 million by UGC

教學科研部講師蔡嘉傑博士與香港理工大學護理學院合作開展虛擬教學項目，以促進跨學科協作學習。項目團隊獲資助港幣 100 萬元，為浸大中醫藥學生及理大護理學生構建虛擬教學平台。以不同臨床場景為題的影片將會上傳至平台，供雙方的學生進行跨院校網上討論。 /

Dr. Chua Ka-kit, Lecturer of CMTR, teamed up with the School of Nursing of the Hong Kong Polytechnic University (PolyU) to develop a virtual teaching project with a view to promoting collaborative learning across disciplines. The project team was granted HK\$1 million to build a virtual teaching platform for Chinese medicine students at HKBU and nursing students at PolyU. Videos of different scenarios in a clinical setting will be uploaded to the platform for cross-institutional online discussion. /

學院調查顯示近 90% 受訪者認同中醫藥可治流感

SCM survey shows nearly 90% of respondents agree that Chinese medicine can treat influenza

由臨床部中醫臨床副教授彭波博士進行的一項調查，成功訪問近 1,600 名居港的成年人，當中 65% 受訪者表示會服用中藥或涼茶預防流感，近 90% 受訪者更認為中醫藥可治癒流感。受訪者又認為中醫藥在治療咳嗽、疲倦、喉嚨痛等流感症狀的成效較為顯著。彭博士獲中醫藥發展基金資助，透過調查了解港人對中醫藥預防及治療流感的看法，從而進一步推廣以中醫藥防治流感。 /

A survey conducted by Dr. Peng Bo, Associate Professor of Practice of CLNC, with around 1,600 adults living in Hong Kong has revealed that 65% of the respondents take Chinese medicine or drink herbal tea to prevent influenza, and almost 90% of the respondents believe that Chinese medicine can successfully treat influenza. The respondents feel that Chinese medicine has more obvious treatment results for influenza symptoms such as cough, fatigue and sore throat. The survey is part of the project led by Dr. Peng with the support of the Chinese Medicine Development Fund to investigate Hong Kong people's perception of flu prevention and treatment in Chinese medicine for the purpose of encouraging a wider adoption of the Chinese medicine regimen to keep the disease at bay. /

浸大中醫抗疫醫療隊獲選感動香江團體

HKBU Chinese Medicine Team Against COVID-19 wins Hong Kong Spirit group award



浸大中醫抗疫醫療隊於香港大公文匯傳媒集團主辦的「慶祝香港回歸祖國 25 周年 — 2022 感動香江」活動中，獲選為「2022 感動香江團體」，以表揚醫療隊在香港爆發新型冠狀病毒第五波疫情時，為確診市民提供醫療服務。校長衛炳江教授、行政副校長暨秘書長鄒靄雲女士、協理副校長（中醫藥發展）兼臨床部主任卞兆祥教授，以及院長呂愛平教授出席 11 月 18 日舉行的頒獎典禮並代表大學領獎。大會讚

揚浸大踐行服務社會的理念，組建一支 60 人的浸大中醫抗疫醫療隊，並成立浸大中醫抗疫遠程醫療中心，提供網上義診、義藥、送藥及情緒支援服務。 /

The HKBU Chinese Medicine Team Against COVID-19 was presented with the Hong Kong Spirit 2022 group award at the 2022 Hong Kong Spirit Event of Celebrating the 25th Anniversary of Hong Kong's Returning to the Motherland, which was organised by the Hong Kong Ta Kung Wen Wei Media Group. The award recognises the team's contributions to providing medical services to people infected with COVID-19 during the fifth wave of the pandemic in Hong Kong. Professor Alexander Wai, President and Vice-Chancellor; Ms. Christine Chow, Vice-President (Administration) and Secretary; Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of CLNC; and Professor Lyu Aiping, Dean of Chinese Medicine, received the recognition on behalf of the University at the award ceremony held on 18 November. The organiser praised the University for realising its vision of serving society by forming the HKBU Chinese Medicine Team Against COVID-19 with 60 members and establishing the HKBU Chinese Medicine Telemedicine Centre Against COVID-19 to provide free online consultations and medicine, drug deliveries and emotional support services. /

中學生參加暑期日營認識中醫藥

Summer day camps immerse secondary school students in Chinese medicine



學院每年舉辦暑期體驗日營，以生動有趣的方式向年輕學生介紹中醫藥。今年，學院在 8 月籌辦三場為期半天的體驗營，吸引近 130 名本地中四和中五學生參加。一眾學生先在網上出席中醫基礎入門課程，再親赴浸大校園體驗中醫藥的奧妙。學生在學院職員的指導下，進行針灸推拿、中藥辨認鑑定、中藥化學及生理學等一系列模擬實驗，並參觀孔憲紹博士伉儷中醫藥博物館和中國銀行（香港）中藥標本中心。 /

The Summer Exploration Day Camp organised by SCM every year is a fun introduction to Chinese medicine for young students. This year, the School hosted three half-day camps in August for close to 130 fourth and fifth-formers from local secondary schools. The participants were given an online taster lecture on the basics of Chinese medicine before they came to the HKBU campus for a more interactive experience. Apart from joining the SCM staff for a series of hands-on experiments on acupuncture and *tui na*, identification of herbal medicines and Chinese medicine chemistry and physiology, the students also toured the Dr. and Mrs. Hung Hin Shiu Museum of Chinese medicine and the Bank of China (Hong Kong) Chinese Medicines Centre. /

獅子會與浸大中醫藥慈善基金 榮獲香港回歸 25 周年企業貢獻大獎

CMCF receives HKSAR 25th Anniversary Enterprise Outstanding Contribution Award



獅子會與香港浸會大學中醫藥慈善基金獲頒「香港回歸 25 周年一企業貢獻大獎」（社會服務組別），以表彰慈善基金在過去 15 年於香港長者服務方面所作的卓越貢獻。慈善基金主席林海涵博士於 7 月 25 日舉行的頒獎禮上代表慈善基金接受殊榮。慈善基金董事謝炎培先生、慈善基金成員楊傑遜女士、副院長（教與學）李敏教授和臨床部副主任楊君軍博士亦有出席活動，分享慈善基金獲獎的喜悅。該獎項由新城廣播有限公司與香港再出發大聯盟為慶祝香港特區成立 25 周年聯合舉辦，以嘉許各大機構對本港經濟發展及社會公益作出的非凡貢獻。 /

Lions & Hong Kong Baptist University Chinese Medicine Charity Foundation (CMCF) was presented with the HKSAR 25th Anniversary Enterprise Outstanding Contribution Award in the Social Service category in recognition of its exceptional contribution to the welfare of elderly in Hong Kong over the past 15 years. Dr. Lam Hoi-ham, Chairman of CMCF, received the award on behalf of CMCF at the ceremony held on 25 July. Mr. Paulman Tse and Ms. Janet Yeung, Director and member of CMCF respectively, Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, and Dr. Yang Junjun, Associate Director of CLNC, were also in attendance to witness the proud moment of CMCF. The Award was jointly organised by Metro Broadcast Corporation Limited and Hong Kong Coalition in celebration of the 25th Anniversary of the establishment of the HKSAR, with the aim of acknowledging organisations with outstanding contributions to the economic growth and social good of Hong Kong. /

學院流動體質檢測站穿梭全港各區服務長者 SCM mobile unit travels around town to serve the elderly



香港浸會大學—賽馬會中醫疾病預防與健康管理中心承蒙香港賽馬會慈善信託基金的支持，於 2020 年 10 月推出流動中醫體質檢測站，以便長者在疫情期間接受免費專業健康諮詢。檢測站採用流動車形式，內設中醫四診儀收集舌像、面像和脈搏資訊，以助中醫師評估長者的健康狀況，再按其體質制定專屬養生方案。檢測站先後到訪多個鄰近安老院舍和社區中心的地點，在 14 個月內惠及近 10,000 名長者。 /

With the support of the Hong Kong Jockey Club Charities Trust, the HKBU-Jockey Club Chinese Medicine Disease Prevention and Health Management Centre introduced a Mobile Chinese Medicine Body Constitution Assessment Station in October 2020 with the mission of giving the elderly free and easy access to professional health advice during the COVID-19 pandemic. The mobile station is a vehicle equipped with the Chinese Medicine Four Diagnostic Instrument which collects tongue and face images as well as pulse information to facilitate the assessment of a person's health condition by a Chinese medicine practitioner, who will then come up with an individualised health regimen based on the person's body constitution. In its 14 months of service, the mobile station has travelled to various locations within easy reach of elderly homes and community centres, serving close to 10,000 senior citizens. /

「浸大養生月」吸引近 3,000 名市民參加 BU Wellness Month attracts close to 3,000 participants



自香港浸會大學—賽馬會中醫疾病預防與健康管理中心在 2018 年 7 月啟用以來，學院便把每年 7 月定為「浸大養生月」，推廣中醫「治未病」的理念。今年，中心再度舉辦健康講座和工作坊，更免費提供中醫四診儀體質檢測服務，並以優惠價發售各種浸大養生產品和名貴中藥材，吸引數千名市民參加。 /

Since the opening of the HKBU-Jockey Club Chinese Medicine Disease Prevention and Health Management Centre in July 2018, the School has designated every July as the “BU Wellness Month” to promote the Chinese medicine concept of preventive care, and this year was no exception. Thousands of members of the public participated in the health talks and workshops organised by the centre, and enjoyed special offer for free trial of the Chinese Medicine Four Diagnostic Instrument and discounted BU Wellness products and prized Chinese medicines. /

年輕中醫師及講師為屯門區居民舉辦健康講座

Young Chinese medicine experts come together to deliver health talks to people in Tuen Mun



一群來自學院的年輕講師和新晉中醫師與屯門地區康健中心合作，在 8 至 9 月為屯門區居民舉辦一系列健康講座。各場講座從中醫角度探討慢性痛症管理、護膚、消化健康、心理健康、過敏、免疫學、認知障礙症等不同主題，吸引逾 300 人現場或線上實時參與。 /

A group of young lecturers and budding Chinese medicine practitioners from SCM joined hands with the Tuen Mun District Health Centre to present a series of health talks to the Tuen Mun community from August to September. The talk series explored a wide range of topics from the Chinese medicine perspective, including chronic pain management, skin care, digestive health, mental health, allergy, immunology and dementia. More than 300 people turned up or tuned in to the live-streamed talks. /

持續及專業教育部講師在電台節目分享實用中醫藥知識

DCPE lecturers share practical knowledge of Chinese medicine on radio show

持續及專業教育部的柯蘭博士、方劍鋒博士和周立敏博士，獲邀擔任香港電台節目《你健康我健康》的客席嘉賓。三位講師在 7 至 9 月播出的多集節目中，與主持和觀眾分享他們的專業知識，主題涵蓋養生茶療、中藥應用和其功效，以及防治新冠肺炎的中醫療法。 /

Dr. O Lan, Dr. Fang Jianfeng and Dr. Zhou Limin from the Division of Continuing and Professional Education of SCM made guest appearances on several episodes of RTHK's radio programme *Healthy Together* which were broadcast between July and September. The three lecturers shared their expert knowledge of tea therapy, the application of Chinese medicines and their benefits, and the Chinese medicine approach to the prevention and treatment of COVID-19 infection with the host and the audience. /

學院參與「文物時尚·荷李活道」2022 向公眾介紹雷生春今昔

SCM introduces the past and present of Lui Seng Chun in
“Heritage Vogue · Hollywood Road” 2022



學院於 11 月 20 日參與「文物時尚·荷李活道」活動，向公眾介紹浸大如何透過「活化歷史建築伙伴計劃」，把雷生春堂活化成中醫診所。學院在活動現場設置攤位，市民除可參加各項遊戲外，更可與古色古香的涼茶銅壺合影，從中探索雷生春堂的歷史點滴和現今用途。是次活動由發展局文物保育專員辦事處主辦，古物古蹟辦事處、元創方、大館和東華三院協辦，致力向大眾推廣保育歷史建築。/

SCM participated in the "Heritage Vogue · Hollywood Road" on 20 November, offering the public an opportunity to learn more about the Lui Seng Chun building, which has been transformed into a Chinese medicine clinic by HKBU under the Revitalising Historic Buildings Through Partnership Scheme. Visitors to

the SCM booth were able to enjoy fun games, take photos with old-fashioned herbal tea vessels while learning interesting facts about the history and current uses of the building. The event was organised by the Commissioner for Heritage's Office of the Development Bureau in collaboration with the Antiquities and Monuments Office, PMQ, Tai Kwun and Tung Wah Group of Hospitals to promote conservation of historic buildings./

學院健康知識叢書廣受好評 SCM health book series well received by public

學院在香港賽馬會慈善信託基金的支持下，出版了一套合共 33 冊的叢書。叢書匯集多個健康主題的實用資訊，內容深入淺出，廣受浸大中醫診所訪客的歡迎。學院已經透過浸大診所網絡、非政府組織等途徑，向公眾派發近 208,000 本書籍。為引發年輕學生對中醫藥的興趣，學院在 8 月捐贈多套叢書予全港中學圖書館。部分書冊亦已於公共圖書館上架，更多書目將於不久將來可供借閱。/

With the support of the Hong Kong Jockey Club Charities Trust, SCM has published a 33-volume book series featuring useful information on a variety of health topics. The books are easy to read and highly popular among visitors of the HKBU Chinese medicine clinics. So far, around 208,000 copies have been distributed to the public through the HKBU clinical network, non-governmental organisations and other channels. To spark young students' interest in Chinese medicine, the School sent out complimentary copies to libraries of secondary schools across the city in August. Some of the volumes are also available at public libraries, with more expected to make it to the shelves soon./



陳永光教授 榮獲浸大傑出校友獎

Professor Chan Wing-kwong honoured with
HKBU Distinguished Alumni Award

學院舊生陳永光教授（中）於 8 月獲大學頒授傑出校友獎，以表揚他在專業領域的卓越成就，以及對大學和社會的重大貢獻。陳教授現為香港註冊中醫學會會長、香港中醫中藥界聯合總會主席，以及港區世界中聯理事協會主席。他在多個中醫藥專業團體身居要職，竭力推動中醫藥的教育、規管工作和發展。SCM alumnus Professor Chan Wing-kwong (middle) was conferred in August the Distinguished Alumni Award by the University in recognition of his outstanding professional achievements as well as his immense contributions to the University and society at large. Professor Chan currently serves as the Chairman of the Hong Kong Registered Chinese Medicine Practitioners Association, the Federation of the Hong Kong Chinese Medicine Practitioners and Chinese Medicines Traders Association, and the World Federation of Chinese Medicine Societies (Hong Kong) Council Members Association. In the many important positions he has held in various Chinese medicine professional associations, Professor Chan has been actively involved in the education, regulation and development of Chinese medicine. /

第八屆傑出校友獎頒獎典禮
3.8.2022



本科生羅籽晴 獲頒友邦獎學金

Undergraduate student Law Tsz-tsing
awarded scholarship by AIA



中醫本科二年級學生羅籽晴（右四）連同另外七名浸大學生於 8 月 2 日舉行的頒獎典禮上，獲頒 2021-22 年度友邦獎學金，以表彰各人在學業上的卓越表現，並積極履行公民責任。友邦保險控股有限公司在 2020 年設立友邦獎學金，承諾投放一億美元，在未來數十年每年資助 100 名本科生就讀香港的大學。每名得獎者在就讀本科課程期間，均可每年獲得港幣五萬元的獎學金。BCM Year 2 student Law Tsz-tsing (4th right) and seven other undergraduate students from HKBU received the AIA Scholarships 2021-22 as a recognition of their

academic excellence and strong sense of civic duty at a ceremony on 2 August. AIA Group Limited established the AIA Scholarships in 2020 and has pledged US\$100 million to sponsor 100 undergraduates every year to pursue studies at universities in Hong Kong over the next few decades. Each recipient will receive an award of HK\$50,000 each year throughout their undergraduate studies. /

本科生楊子晴 在本地和全國比賽取得佳績

Undergraduate student Michelle Yeung shines at local and national competitions

中醫本科六年級學生楊子晴獲頒港幣 15 萬元的創新科技獎學金。該獎學金由創新科技署、滙豐銀行及香港青年協會於 2011 年設立。頒獎典禮於 6 月 6 日舉行，由時任香港特別行政區行政長官林鄭月娥女士擔任主禮嘉賓。楊同學早前亦獲選為香港區五位青年代表之一，與全國各地近 33,000 名參加者競逐成為 2022 年「全國向上向善好青年」，並成功入圍最後遴選。該比賽於今年首度接受香港區報名參賽。此外，楊同學於 5 月亮相中央廣播電視總台節目《大灣區之聲》，分享自幼立志成為中醫師的故事。

BCM Year 6 student Michelle Yeung Tsz-ching has received a scholarship of HK\$150,000 from the Innovation Technology Scholarship Award jointly established by the Innovation and Technology Commission, The Hongkong and Shanghai Banking Corporation Limited and The Hong Kong Federation of Youth Groups in 2011. The award ceremony on 6 June was officiated by Mrs. Carrie Lam, then-Chief Executive of the Hong Kong Special Administrative Region. Michelle was also one of five students selected locally to enter the 2022 National Outstanding Youths contest in which she competed against nearly 33,000 candidates from across the country and reached the final. It is the first time that the competition has accepted entries from Hong Kong. Michelle's story of how she found her calling in Chinese medicine at a young age was featured in the China Media Group programme "Radio The Greater Bay Area" in May. /



本科生蘇熙驊 獲頒香港賽馬會獎學金

Undergraduate student So Hei-wa wins scholarship from The Hong Kong Jockey Club

中醫本科三年級學生蘇熙驊（左）與另外四名浸大本科生獲頒 2021-22 年度香港賽馬會獎學金。該獎學金旨在表揚一眾學業表現出色且熱心參與社會事務的學生，自 1998 年成立以來，已資助逾 880 名香港和內地的傑出學生，他們均具備成為未來領袖的優秀特質和超卓才能。BCM Year 3 student So Hei-wa (left) was among the five HKBU undergraduate students to be awarded the 2021-22 Hong Kong Jockey Club Scholarships in recognition of their outstanding academic performance and commitment to serving the

community. Since 1998, The Hong Kong Jockey Club Scholarships have supported more than 880 outstanding students from Hong Kong and the Mainland who demonstrated exceptional qualities and abilities to become future leaders. /



莊偉波博士 Dr. CHONG Wai-po

教學科研部副教授 Associate Professor, Teaching and Research Division

莊博士於香港大學取得免疫學碩士及博士學位，再赴美國馬里蘭州貝塞斯達的國立衛生研究所屬下國立眼科研究所從事免疫相關的博士後研究工作。及後經中山大學「百人計劃」聘任為眼科中心國家重點實驗室副教授，至2022年加入學院擔任副教授。莊博士致力研究免疫調節和自身免疫的細胞和分子機制，從而發現治療自身免疫性疾病的新型藥物。相關研究成果於《Immunity》、《Journal of Experimental Medicine》、《Journal of Autoimmunity》、《Hepatology》、《Journal of Infection》等權威期刊上發表。Dr. Chong obtained his MPhil and PhD degrees in immunology from the Department of Paediatrics and Adolescent Medicine at The University of Hong Kong. He received postdoctoral training in immunology from the National Eye Institute at National Institutes of Health in Bethesda, Maryland, US. After that, he was recruited by Sun Yat-sen University through its "100 Top Talents Program" as Associate Professor at the Key State Laboratory of Ophthalmology. He joined SCM as Associate Professor in 2022. Dr. Chong's research centers on the cellular and molecular mechanisms involved in immunoregulation and autoimmunity, and discovering novel therapeutic drugs for autoimmune diseases. His works on autoimmunity have been published in prestigious journals, including *Immunity*, *Journal of Experimental Medicine*, *Journal of Autoimmunity*, *Hepatology* and *Journal of Infection*.

許軍博士 Dr. XU Jun

教學科研部助理教授 Assistant Professor, Teaching and Research Division

許博士在澳門大學取得中藥學碩士學位，並於浸大取得生藥學博士學位。畢業後在學院接受博士後培訓並擔任教學科研部研究助理教授，於2022年獲委任為助理教授。

許博士的研究興趣集中在生藥學領域，特別是中藥炮製化學與炮製藥理學，以及中草藥與腸道菌群互作分子機制。After graduating from University of Macau with a master's degree in Chinese medicinal science, Dr. Xu went on to obtain a doctoral degree in pharmacognosy from HKBU and receive postdoctoral training at SCM. He served as Research Assistant Professor at CMTR before being appointed as Assistant Professor in 2022. Dr. Xu conducts extensive research on pharmacognosy, with a particular interest in processing chemistry and pharmacology of Chinese *materia medica*, and molecular mechanisms of the interplay between herbal medicines and gut microbiota.



于媛媛博士 Dr. YU Yuanyuan

教學科研部助理教授 Assistant Professor, Teaching and Research Division

于博士在香港大學醫學院取得生物化學博士學位，畢業後即加入學院接受博士後訓練，自2019年擔任研究助理教授，並於2022年獲委任為助理教授。于博士目前主力研究核酸適配體的優化篩選方法、核酸適配體的轉化醫學及藥物發現，以及核酸適配體的結構生物學。Dr. Yu obtained her PhD in biochemistry from the Faculty of Medicine at The University of Hong Kong. Upon graduation, she joined SCM for postdoctoral training and was subsequently appointed Research Assistant Professor in 2019 and Assistant Professor in 2022. Her current research interests include optimisation of the aptamer selection methodologies; aptamer-based translational medicine and drug discovery; and aptamer structural biology.

聯絡我們
Contact Us

香港浸會大學中醫藥學院

九龍塘浸會大學道七號賽馬會中醫藥學院大樓

School of Chinese Medicine, Hong Kong Baptist University

Jockey Club School of Chinese Medicine Building,
7 Baptist University Road, Kowloon Tong, Kowloon.

院長辦公室 Dean's Office

四樓 4/F

電話 Tel (852) 3411 2457
傳真 Fax (852) 3411 2917
電郵 Email scmd@hkbu.edu.hk

教學科研部 Teaching and Research Division

四樓 4/F

電話 Tel (852) 3411 2481
傳真 Fax (852) 3411 2461
電郵 Email cmtr@hkbu.edu.hk

技術開發部 Technology Development Division

四樓 4/F

電話 Tel (852) 3411 2945
傳真 Fax (852) 3411 2902
電郵 Email scmtdd@hkbu.edu.hk

臨床部 Clinical Division

三樓 3/F

電話 Tel (852) 3411 2968 / (852) 3411 2988
傳真 Fax (852) 3411 2929
電郵 Email scmcl@hkbu.edu.hk

持續及專業教育部 Division of Continuing & Professional Education

四樓417室 Rm417, 4/F

電話 Tel (852) 3411 2912 / (852) 3411 5748
傳真 Fax (852) 3411 2918
電郵 Email dcpe@hkbu.edu.hk

秘書處 Secretariat

四樓 4/F

電話 Tel (852) 3411 5387
傳真 Fax (852) 3411 2902
電郵 Email scm@hkbu.edu.hk

學院網頁 | SCM Website
<http://scm.hkbu.edu.hk>

